A Glimpse Into The Expert Outlook On Omega Therapeutics Through 4 Analysts
Portfolio Pulse from Benzinga Insights
Over the past three months, four analysts have evaluated Omega Therapeutics (NASDAQ:OMGA), with ratings ranging from bullish to bearish. The average 12-month price target is $10.5, with a high of $12.00 and a low of $6.00. Recent ratings include 'Buy' and 'Outperform' from HC Wainwright & Co., Wedbush, and Raymond James, while Chardan Capital lowered its target from $7.00 to $6.00. Omega Therapeutics has shown significant revenue growth but faces challenges with high debt levels and low ROE.
August 15, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Omega Therapeutics (NASDAQ:OMGA) has received mixed analyst ratings over the past three months, with an average 12-month price target of $10.5. Recent ratings include 'Buy' and 'Outperform', but Chardan Capital lowered its target from $7.00 to $6.00. The company has shown significant revenue growth but faces challenges with high debt levels and low ROE.
The mixed analyst ratings and the average price target of $10.5 suggest a neutral short-term impact on OMGA's stock price. While the company has shown significant revenue growth, challenges such as high debt levels and low ROE may offset positive sentiments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100